P.T. Jyothi Datta

Mumbai, March 7

The one-year-old product patent regime in India, it seems, is fighting fit.

Torrent has opposed the grant of a patent on Astra Zeneca's cholesterol drug Rosuvastatin, while Ranbaxy has filed for pre-grant opposition against Pfizer's anti-fungal drug Voriconazole.

Ajanta Pharma has opposed Eli Lilly's patent application on erectile dysfunction drug Tadalafil, and Cipla and Hetero have opposed Wockhardt's patent application on anti-bacterial drug Nadifloxacin.

Meditab Specialities has opposed the grant of a patent to the Gilead-Roche combine on its bird-flu drug Oseltamivir, patent attorneys told

Business Line


But this is just a peep into the argumentative world of pre-grants, with drug-makers fighting at least 100-odd such oppositions at patent offices across the country, a legal expert said.

A pre-grant opposition allows people to contest a patent application filed by a company at the patent office.

After hearing out the patent-holder and the opposition, the patent office eventually grants or rejects the drug firm's application for a patent.

Only recently, the Indian Patent office rejected Novartis's claim for a patent on imatinib mesylate, a cancer drug sold by it under the brand name Gleevec.

According to a patent lawyer, there are more than 40 pre-grant oppositions in Delhi, over 20 in Chennai, an excess of 15 in Mumbai, and a similar number in Kolkata.

In Delhi alone, Ranbaxy has about 12 pre-grant oppositions and Torrent about 15, he added.

Ranbaxy is also reported to be opposing Eli Lilly's patent application on Tadalafil and Torrent is opposing Astra Aktiebolag's patent application on a pharmaceutical formulation of ulcer drug Omeprazole, a lawyer said.

Mr Ramesh Adige, Executive Director of Ranbaxy, said: "We do not comment on specific issues. However, our intellectual property team makes a careful analysis on a case-to-case basis to examine and assess the use of the provisions available under the Indian Patent Law for pre-grant and post-grant opposition."

Admitting that pre-grant oppositions are being actively fought out at different centres, Calcutta-based patent firm S. Majumdar & Co said that it has filed over 40 pre-grant oppositions at patent offices across the country.

And Gujarat-based Torrent Pharma accounts for about 50 percent of these opposition cases, according to Mr S. Majumdar, patent attorney.

Related Stories:
First phase scrutiny to cover 3,000 drug patent requests
Demand perks up for IP experts in pharma sector
Avian flu drug: Who owns the patent?

(This article was published in the Business Line print edition dated March 8, 2006)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.